It is Poised to be a Bull Market for Ascendis Pharma A/S ADR (ASND)

With 0.6 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.55 million shares. The 52-week range on ASND shows that it touched its highest point at $183.00 and its lowest point at $111.09 during that stretch. It currently has a 1-year price target of $222.06. Beta for the stock currently stands at 0.39.

Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of ASND was down-trending over the past week, with a drop of -12.09%, but this was up by 9.73% over a month. Three-month performance surged to 25.13% while six-month performance rose 18.04%. The stock gained 11.23% in the past year, while it has gained 9.86% so far this year. A look at the trailing 12-month EPS for ASND yields -6.29 with Next year EPS estimates of 1.86. For the next quarter, that number is -1.55. This implies an EPS growth rate of 35.26% for this year and 139.16% for next year.

Float and Shares Shorts:

At present, 60.37 million ASND shares are outstanding with a float of 59.90 million shares on hand for trading.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for ASND since 7 analysts follow the stock currently. There are 6 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 1 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential.

EPS: Estimates vs Actual

It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$5.76574 being high and -$7.57235 being low. For ASND, this leads to a yearly average estimate of -$6.84201. Based on analyst estimates, the high estimate for the next quarter is $0.02 and the low estimate is -$1.99. The average estimate for the next quarter is thus -$0.81.